Advances in palliative chemotherapy for advanced pancreatic cancer
- VernacularTitle:晚期胰腺癌姑息性化疗进展
- Author:
Yiyi FU
;
Tianshu LIU
- Publication Type:Journal Article
- Keywords:
advanced pancreatic cancer;
palliative chemotherapy
- From:
China Oncology
2009;19(8):585-589
- CountryChina
- Language:Chinese
-
Abstract:
With a high invasive ability and poor prognosis, the morbidity of pancreatic cancer is about 98%.Combination of chemotherapy and radiotherapy is the primary management for locoregionally advanced pancreatic cancer, but its efficacy is limited. Results from a number of meta-analysis have confirmed that gemcitabine is associated with significantly better clinical response and one-year overall survival rates;therefore, currently gemcitabine is the standard chemotherapy for advanced pancreatic cancer. Gemcitabine-based multi-drug regimens may have potentially favorable effects on patients' survival. However, evidence from phase Ⅲ clinical trials is lacking. Newer chemotherapy and targeted therapy agents are clearly needed for patients with advanced pancreatic cancer.
